Moxisylyte hydrochloride

Moxisylyte hydrochloride (CAS No.: 964-52-3) is a synthetic small molecule adrenergic modulator, commonly classified as a selective alpha one adrenergic receptor antagonist with reported preference for the alpha one A subtype, and it is widely used as a pharmacological tool compound in cardiovascular, neurovascular, and smooth muscle signaling research relevant to biomedical discovery workflows. In mechanistic studies, it functions as a competitive blocker of catecholamine driven receptor activation, thereby attenuating Gq phospholipase C inositol trisphosphate and diacylglycerol signaling, reducing intracellular calcium mobilization, and promoting relaxation responses in alpha one responsive smooth muscle systems, including vascular and cavernous tissue models under controlled laboratory conditions. Available literature level descriptions indicate activity consistent with pharmacology typically observed from nanomolar to micromolar concentration ranges for receptor antagonists of this class, while exact potency values vary with receptor subtype, species background, assay format, and endpoint selection. In vitro, the compound is applied in receptor binding and functional antagonism assays, contractility studies in isolated tissue preparations, and pathway deconvolution experiments designed to quantify noradrenergic tone and downstream second messenger effects; in vivo, it is used in preclinical animal studies to investigate alpha adrenergic contributions to hemodynamic regulation and autonomic dysfunction phenotypes. In translational screening contexts, it is commonly incorporated as a reference antagonist for target validation, selectivity benchmarking against related adrenergic receptors, and structure activity relationship programs focused on adrenergic pathway modulation, with concentrations or doses used in experiments typically depending on specific experimental designs and research objectives.